Wednesday, September 21, 2016 8:57:16 AM
Posted by Amy Steele on Sep 21st, 2016 // No Comments
Clovis Oncology Inc. (NASDAQ:CLVS) had its target price increased by investment analysts at Stifel Nicolaus from $30.00 to $45.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.
Stifel Nicolaus’ price objective would suggest a potential upside of 29.20% from the stock’s current price.
Several hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new stake in Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. purchased a new position in shares of Clovis Oncology during the second quarter worth $154,000. Legal & General Group Plc increased its position in shares of Clovis Oncology by 56.8% in the first quarter. Legal & General Group Plc now owns 8,483 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 3,072 shares during the last quarter. CIBC World Markets Inc. increased its position in shares of Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Clovis Oncology during the first quarter worth $233,000. Institutional investors own 98.46% of the company’s stock.
Recent CLVSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/18/2023 04:15:24 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/11/2023 04:09:55 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/11/2023 04:05:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/11/2023 03:43:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 01:37:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:08:05 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM